Search

Displaying results 2951 - 2960 of 5900 in total
  1. Drug

    Dextromoramide

    go.drugbank.com/drugs/DB01529
    ExperimentalIllicit

    An opioid analgesic structurally related to methadone and used in the treatment of severe pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1070)

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  2. Drug

    Propofol

    go.drugbank.com/drugs/DB00818
    ApprovedInvestigationalVet approved

    Propofol may be used prior to diagnostic procedures requiring anaesthesia, in the management of refractory status epilepticus, and for induction and/or maintenance of anaesthesia prior to and during surgeries … IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications.

    Products: Propofol Emulsion for Injection or Infusion (1% w/v) with MCT-LCT (1% w/v)-SPIVA, Injection or Infusion 1% w/v)
  3. Drug

    Secobarbital

    go.drugbank.com/drugs/DB00418
    ApprovedVet approved

    Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the...

  4. Drug

    Crotamiton

    go.drugbank.com/drugs/DB00265
    Approved

    It is a colorless to slightly yellowish oil, having a faint amine-like odor. It is miscible with alcohol and with methanol.

    Products: CROTOCORT CREAM 10% W/W, Crotocort Lotion 10% w/w
  5. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    By replacing deficient ALP, treatment with Asfotase Alfa aims to improve the elevated enzyme substrate levels and improve the body's ability to mineralize bone, thereby preventing serious skeletal and … Asfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP).

  6. Drug

    Eravacycline

    go.drugbank.com/drugs/DB12329
    ApprovedInvestigational

    Eravacycline has demonstrated superior potency to that of antibiotics that are currently being marketed for intraabdominal infections [A38727]. … This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority

  7. Drug

    Tisotumab vedotin

    go.drugbank.com/drugs/DB16732
    ApprovedInvestigational

    Tisotumab vedotin targets TF-expressing cells to deliver MMAE to induce direct cytotoxicity and bystander killing of neighboring cells. … Tisotumab vedotin is the first TF-directed ADC [A238914] that works by binding to TFs expressed on solid tumours.

  8. Drug

    Thenalidine

    go.drugbank.com/drugs/DB04826
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to concerns involving neutropenia.

  9. Drug

    Floctafenine

    go.drugbank.com/drugs/DB08976
    ApprovedWithdrawn

    Floctafenine is an anti-inflammatory analgesic similar in action to aspirin. Floctafenine inhibits prostaglandin synthesis.

  10. Drug

    Poliomyelitis virus type 1 (live, attenuated)

    go.drugbank.com/drugs/DB16578
    Investigational

    Mixtures: POLIO SABIN ONE AND THREE (ORAL) VACCINE